Carlsmed’s US$10 Million Series A financing

Morrison & Foerster LLP advised Carlsmed, Inc. on the deal.

Carlsmed, Inc. announced its US$10 million Series A financing, led by U.S. Venture Partners (USVP). Carlsmed will use the financing to commercialize the aprevo family of spine deformity correction devices. Carlsmed was recently granted 510(k) clearance and Breakthrough Device Designation by the FDA for aprevo, making it the first implant ever to receive both Breakthrough Device Designation and 510(k) market clearance from the FDA. USVP is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies.

The MoFo team was led by San Diego partner Jim Krenn (Picture), and associates Brennen Brodersen and Carey Hughes. Additional support was provided by Government Contracts & Public Procurement partners Charles Capito and Tina Reynolds, as well as Federal Tax partner Shane Shelley, National Security Compliance partner Panagiotis Bayz, Emerging Companies & Venture Capital partner Steve Rowles, and Executive Compensation partner Amanda Hines Gold.

Involved fees earner: Panagiotis Bayz – Morrison Foerster; Brennen Thomas Brodersen – Morrison Foerster; Charles Capito III – Morrison Foerster; Amanda Hines Gold – Morrison Foerster; Carey Hughes – Morrison Foerster; Jim Krenn – Morrison Foerster; Tina Reynolds – Morrison Foerster; Steve Rowles – Morrison Foerster; Shane Shelley – Morrison Foerster;

Law Firms: Morrison Foerster;

Clients: Carlsmed, Inc.;

Author: Ambrogio Visconti